Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Asian Stocks Slip as Oil Prices Surge and Fed Signals Inflation Risks 
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
EU Warns of Response as U.S. Considers 25% Tariffs on Car Imports 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
Oil Prices Fall as Iran Proposes New Deal Amid Ongoing U.S. Tensions 
Google Secures Pentagon AI Deal for Classified Projects 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
AI Stocks Rally in Asia as Oil Surge and Hawkish Central Banks Shake Global Markets 
Gold Prices Hold Steady as Iran War and Interest Rate Outlook Weigh on Markets 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
US-Iran Conflict Escalates Amid Oil Blockade and Rising Global Tensions 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Johnson & Johnson acquires Abiomed medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices such as the heart pump. The company invested $16.6 million in the acquisition deal.
Johnson & Johnson revealed its latest investment on Tuesday, Nov. 1, and it was described as its biggest purchase in almost six years. The buyout was a strategic move as the company is looking to bolster its cardiovascular business.
It was noted that the decision was made at a time when Johnson & Johnson was spinning off its consumer health business unit so it could focus on works related to pharmaceuticals and medical devices. The addition of Abiomed to its portfolio through the acquisition deal is expected to scale up its medical device division.
As part of the agreement, the company will pay $380 for each Abiomed share. It will also hand out another $35 per share in cash if the Danvers, Massachusetts-headquartered medical device maker achieves new commercial and clinical milestones, as per CNBC.
Abiomed is known to develop heart pumps and other technology for the treatment of coronary artery disease and heart failure. Its Impella heart pump device is typically used for patients suffering from severe coronary artery disease.
This Johnson & Johnson and Abiomed acquisition agreement is expected to be completed by early next year. Once done, it will help J&J broaden its position as a thriving cardiovascular innovator while also building its medical device segment.
“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” Johnson & Johnson’s chief executive officer, Joaquin Duato, said in a press release.
The CEO added, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”
Finally, Johson & Johnson said that Abiomed will be placed under its medical technology unit but that, despite the acquisition, it will continue to operate as a standalone business.
